The role of Gut ecosystem in obesity and colorectal patients
Ontology highlight
ABSTRACT:
DISEASE(S): Neoplasms
PROVIDER: 2509326 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
Similar Datasets
Project description:Probiotic bacteria, specific representatives of bacterial species that are a common part of the human microbiota, are proposed to deliver health benefits to the consumer by modulation of intestinal function via largely unknown molecular mechanisms. To explore in vivo mucosal responses of healthy adults to probiotics, we obtained transcriptomes in an intervention study following a double-blind placebo-controlled cross-over design. In the mucosa of the proximal small intestine of healthy volunteers, probiotic strains from the species Lactobacillus acidophilus, L. casei and L. rhamnosus each induced differential gene regulatory networks and pathways in the human mucosa. Comprehensive analyses revealed that these transcriptional networks regulate major basal mucosal processes, and uncovered remarkable similarity to response profiles obtained for specific bioactive molecules and drugs. This study elucidates how intestinal mucosa of healthy humans perceive different probiotics and provides avenues for rationally designed tests of clinical applications. Keywords: mucosal response of healthy adult humans to lactic acid bacteria This study was set up according to a randomised double-blind cross-over placebo-controlled design. It contains transcriptional profiles from biopsies from 7 healthy individuals after oral intake of three different Lactobacillus species or placebo control. In total, this study includes data from 7 individuals x 4 treatments=28 arrays.
2010-09-08 | E-GEOD-18741 | biostudies-arrayexpress
Project description:Interventions: Group I (experimental): PROBIOTIKOS nº 2 (Brand Name), composed of a mixture of Lactobacillus rhamnosus (2 x 109 CFU/caps), Bifidobacterium breve (2 x 109 CFU/caps) and Lactobacillus casei (1x109 CFU/caps). Group II (control): Placebo compound by Maltodextrin 330 mg/caps. All two groups will receive 1 capsule of treatments or placebo orally twice a day with food breakfast/dinner) for three consecutive days before surgery (from day -3 to day -1 included). The day of surgery (day 0) the dose is 2 capsules in the early morning, offer it with a little amount of water. Treatments or placebo will be resumed postoperatively twice a day with food (breakfast/dinner) on day +2 until day +7 for a total of 10 days of treatment (20 doses).
Primary outcome(s): • Postoperative diarrhea incidence, measuring time: day +8 and day +30 • Postoperative infectious complications incidence, measuring time: day +8 and day +30 • Quality of Live (FACT-C questionnaire), measuring time: day -4; day +8 and day +30
Study Design: Allocation: Randomized controlled trial. Masking: Double Blind. Control group: Placebo. Assignment: Parallel. Purpose: Other
| 2571458 | ecrin-mdr-crc
Project description:Intervention 1: group two take a combination of probiotic and honey (two probiotic capsules and 30 grams honey per day, one capsule and 15 grams honey in the morning after breakfast and another one capsule in the evening, and 15 grams honey at night). Intervention 2: group three are the control group receive two placebo capsules (containing 500 mg of corn starch) per day, one capsule in the morning after breakfast and another one in the evening. Intervention 3: group one take probiotics )contained: Lactobacillus casei 1.5 × 109 CFU, Lactobacillus acidophilus 1.5 × 1010 CFU, Lactobacillus rhamnosus 3.5 × 109 CFU, Lactobacillus bulgaricus 2.5 × 108 CFU, Bifidobacterium breve 1 × 1010 CFU, Bifidobacterium longum 5 × 108 CFU and Streptococcus thermophilus 1.5 × 108 CFU per 500 mg(; two probiotic capsules per day, one capsule in the morning after breakfast and another one in the evening.;Treatment - Drugs;Treatment - Drugs;Treatment - Drugs;group two take a combination of probiotic and honey (two probiotic capsules and 30 grams honey per day, one capsule and 15 grams honey in the morning after breakfast and another one capsule in the evening, and 15 grams honey at night);group three are the control group receive two placebo capsules (containing 500 mg of corn starch) per day, one capsule in the morning after breakfast and another one in the evening;group one take probiotics )contained: Lactobacillus casei 1.5 × 109 CFU, Lactobacillus acidophilus 1.5 × 1010 CFU, Lactobacillus rhamnosus 3.5 × 109 CFU, Lactobacillus bulgaricus 2.5 × 108 CFU, Bifidobacterium breve 1 × 1010 CFU, Bifidobacterium longum 5 × 108 CFU and Streptococcus thermophilus 1.5 × 108 CFU per 500 mg(; two probiotic capsules per day, one capsule in the morning after breakfast and another one in the evening
Primary outcome(s): Diarrhea grade. Timepoint: Weekly from one week before radiotherapy until end of treatment. Method of measurement: Common Toxicity Criteria system.;Stool consistency score. Timepoint: Weekly from one week before radiotherapy until end of treatment. Method of measurement: Bristol scales.;Blood cell counts. Timepoint: Weekly from one week before radiotherapy until end of treatment. Method of measurement: cell counter machine.;Serum IgA level. Timepoint: Weekly from one week before radiotherapy until end of treatment. Method of measurement: Autoanalyzer machine.
Study Design: Randomization: Randomized, Blinding: Not blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment.
| 2485704 | ecrin-mdr-crc
Project description:Probiotic bacteria, specific representatives of bacterial species that are a common part of the human microbiota, are proposed to deliver health benefits to the consumer by modulation of intestinal function via largely unknown molecular mechanisms. To explore in vivo mucosal responses of healthy adults to probiotics, we obtained transcriptomes in an intervention study following a double-blind placebo-controlled cross-over design. In the mucosa of the proximal small intestine of healthy volunteers, probiotic strains from the species Lactobacillus acidophilus, L. casei and L. rhamnosus each induced differential gene regulatory networks and pathways in the human mucosa. Comprehensive analyses revealed that these transcriptional networks regulate major basal mucosal processes, and uncovered remarkable similarity to response profiles obtained for specific bioactive molecules and drugs. This study elucidates how intestinal mucosa of healthy humans perceive different probiotics and provides avenues for rationally designed tests of clinical applications. Keywords: mucosal response of healthy adult humans to lactic acid bacteria
2010-09-08 | GSE18741 | GEO
Project description:Samples were obtained as part of a randomized, double blind, placebo-controlled, phase IIb study to determine the effects of myo-inositol in smokers with bronchial dysplasia. Smokers with greater than 1 site of dysplasia identified by autofluorescence bronchoscopy-directed biopsy were randomly assigned to receive oral placebo or myo-inositol, 9 g once/day for two weeks and then twice/day for 6 months. Cytologically normal airway epithelial cells were obtained via bronchoscopy from the right or left mainstem bronchus at baseline and 6 months post-treatment with myo-inositol or placebo from 69 study participants (n=138 samples). The RNA from these samples was isolated and used to prepare libraries for mRNA sequencing. Subjects were classified by response according to their change in dysplasia rate after 6-months. Among subjects with a complete response in the myo-inositol arm, there was a significant decrease in a gene expression signature reflective of PI3K activation.
2016-09-26 | GSE86422 | GEO
Project description:Transcriptional profiling of probiotic Lactobacillus rhamnosus strain GG mid-exponential pH-controlled bioreactor cultures before and after exposure to bovine bile (0.2% ox gall). Keywords: bile, stress response Cell samples from four biological replicates were harvested right before (time point 0 min) and 10, 30 and 120 min after bile treatment. Each sample was compared to a common reference sample (time point 0 min, mid-exponential growth phase Lactobacillus rhamnosus GG cultures). A total of 12 hybridizations were performed using balanced dye-swap design. Dyes were balanced between compared sample pairs and between biological replicates.
2011-01-01 | E-GEOD-22536 | biostudies-arrayexpress
Project description:Interventions: Black seed capsule (containing fresh black seed powder) in the amount of 1000 mg three times a day (it is better to take black seed capsule 2 hours before or 2 hours after a meal)..
Primary outcome(s): Cancer antigen 19-9 (CA19-9). Timepoint: Baseline, 3 months following the treatment and the end of treatment. Method of measurement: Blood test.;Carcino Embryonic Antigen (CEA). Timepoint: Baseline, 3 months following the treatment and the end of treatment. Method of measurement: Blood test.
Study Design: Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment.
| 2496470 | ecrin-mdr-crc
Project description:Intervention 1: Fish oil /intervention. 1200mg (providing omega-3 420 mg EPA and 280 mg DHA) 5 times daily for 8 weeks after starting chemotherapy. Intervention 2: Probiotics/ intervention. 3 gr Granule contains the following probiotic strains: L.acidophilus, L. lactis, L. casei subsp, L. longum, L. bifidum, L. infantis twice a day for 4 weeks after starting chemotherapy. Intervention 3: Sunflower oil /control 1200mg 5 times daily for 8 weeks after starting chemotherapy. Intervention 4: Lactose / control 3 gr Granule contains: Lactose, Maltodextrin, Citric Acid, Ascorbic Acid, Skim Milk Powder, and Sugar twice a day for 4 weeks after starting chemotherapy.;Treatment - Drugs;Treatment - Drugs;Placebo;Placebo;Fish oil /intervention. 1200mg (providing omega-3 420 mg EPA and 280 mg DHA) 5 times daily for 8 weeks after starting chemotherapy;Probiotics/ intervention. 3 gr Granule contains the following probiotic strains: L.acidophilus, L. lactis, L. casei subsp, L. longum, L. bifidum, L. infantis twice a day for 4 weeks after starting chemotherapy;Sunflower oil /control 1200mg 5 times daily for 8 weeks after starting chemotherapy;Lactose / control 3 gr Granule contains: Lactose, Maltodextrin, Citric Acid, Ascorbic Acid, Skim Milk Powder, and Sugar twice a day for 4 weeks after starting chemotherapy
Primary outcome(s): Quality of life. Timepoint: Before starting chemotherapy and supplementationa nd after completion of supplementation and chemotherapy. Method of measurement: EORTC QLQ C-30.
Study Design: Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention.
| 2476898 | ecrin-mdr-crc
Project description:Before sorting, cells were washed twice in 1X PBS buffer (DPBS without calcium chloride and magnesium chloride; Sigma Aldrich, D8537) and labelled with 7-AAD (BD Pharmingen, 51-68981E) for live/dead differentiation and FITC-conjugated antibody [anti-CD47 (BD Pharmingen, 556045) for A375 and anti-CD81 (BD Pharmingen, 551108) for Jurkat].
2019-05-31 | GSE130578 | GEO
Project description:Interventions: 0.1% vitamin K1 ointment twice daily
Placebo ointment twice daily
Primary outcome(s): The number of acneiform eruptions of right and left lesions(face, neck, or chest) of the same patient before and after treatment
Study Design: Parallel Randomized
| 2623509 | ecrin-mdr-crc